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Abstract
Background: Data on the immunization practices in pediat-
ric chronic kidney disease (CKD) patients are scarce. The pur-
pose of this study was to evaluate current vaccination prac-




tices for children on dialysis across European pediatric ne-
phrology centers. Methods: A total of 18 tertiary pediatric 
nephrology centers from 12 European countries were in-
cluded in the study. The data on universal national immuni-
zation programs and immunization practices for children 
with chronic disease or risk were recorded from European 
Center for Disease Prevention and Control and the World 
Health Organization. The immunization practices and center 
protocols for monitoring antibody titers after vaccination in 
dialysis patients were obtained through a questionnaire. Re-
sults: All centers included in the study recommended immu-
nization against hepatitis B virus (HBV), diphtheria, tetanus, 
pertussis, Hemophilus influenzae type b (Hib), poliomyelitis, 
measles, mumps, rubella (MMR), and streptococcus pneu-
monia in dialysis patients. In 16 centers, dialysis patients 
were vaccinated against influenza virus annually. HBV pro-
tective antibody titers were measured in 17 centers (during 
dialysis period in 14 centers, during pre-renal transplanta-
tion preparations in 14 centers or in both times in 11 cen-
ters). Hepatitis A virus (HAV) was reported to be followed in 
13 centers, in 8 centers during dialysis period, and in 11 cen-
ters during pre-RTx preparations. MMR and varicella-zoster 
virus (VZV) protective antibody titers were measured during 
the dialysis period or before renal transplantation (RTx) in 12 
and 15 centers, respectively, and in 6 centers both titers were 
checked both times. Conclusion: There are variations in vac-
cination practice across Europe. Children with CKD, those 
undergoing dialysis, and transplant candidates should re-
ceive age-appropriate vaccinations before RTx as well as be-
fore the transition to adult nephrology clinics and antibody 
levels should be monitored to evaluate the immunization 
status before and after RTx. © 2017 S. Karger AG, Basel
Introduction
Immunization is among the most efficient strategies to 
decrease mortality and morbidity due to infections. There 
are national differences in the recommended immuniza-
tion schedule for healthy children in Europe, depending 
on the epidemiology of diseases [1]. Immunization 
against diphtheria, tetanus, pertussis, Hemophilus influ-
enzae type b (Hib), poliomyelitis, measles, mumps, and 
rubella (MMR) is recommended for all healthy children, 
while vaccination against hepatitis A and B viruses (HAV 
and HAB, respectively), varicella-zoster virus (VZV), hu-
man papillomavirus, rotavirus, Mycobacterium tubercu-
losis, influenza virus, and pneumococcus may vary sig-
nificantly among European countries [1, 2]. While epide-
miological patterns of disease are slower to change, 
worldwide travel and immigration patterns can put im-
munocompromised children at greater risk.
Along with the achievements in technology and treat-
ment of chronic diseases, today the number of children 
surviving with chronic diseases has increased. Children 
on dialysis, with chronic kidney disease (CKD) stages 2–5 
and those with renal transplants (RTx) are at increased 
risk for vaccine-preventable infections, which are signifi-
cant causes of morbidity and mortality [3–6]. These pa-
tients are vulnerable to infections because of the altera-
tions in humoral and cellular immune response, which 
are adversely affected by uremic toxins, malnutrition, and 
immunosuppressive medications [7, 8]. Children with 
CKD should receive all the recommended childhood im-
munizations according to the standard schedule when-
ever possible [3]. The completion of the vaccination 
schedule before RTx is of particular importance [3, 7, 9]. 
Studies suggest that children with CKD and RTx candi-
dates should also be protected against varicella, influenza, 
hepatitis B, and Streptococcus pneumoniae, if not includ-
ed in their national universal immunization schedule [3, 
4, 9]. Although vaccination in children with CKD is safe, 
vaccination coverage among children with CKD remains 
low due to safety concerns and doubts about vaccine im-
munogenicity and efficacy [4, 5]. In addition, data on the 
immunization practices in pediatric CKD and dialysis pa-
tients are scarce. Available guideline recommendations 
for children with CKD are derived from small or single 
center studies, or represent the opinion of a group of ex-
perts. Therefore, immunization recommendations vary 
between countries and even between different health au-
thorities [4]. 
In this study, we aimed to evaluate current vaccination 
practices for children with CKD and those on dialysis 
across European pediatric nephrology centers. 
Patients and Methods
A survey was sent to all members of the European Society for 
Pediatric Nephrology dialysis working group in 2015. A total of 18 
tertiary pediatric nephrology centers from 12 European countries 
(Belgium, Czech Republic, Finland, France, Germany, Greece-2 
centers, Italy-3 centers, Lithuania, Poland, Spain, Turkey-4 cen-
ters, and United Kingdom) responded to the survey. There were 
357 prevalent dialysis patients (205 peritoneal dialysis [PD] and 
152 hemodialysis [HD] patients) in these centers in 2014.
Universal national immunization programs and immunization 
practices for children with chronic diseases or risk were recorded 
from European Center for Disease Prevention and Control and the 
World Health Organization [1, 2]. The immunization practices for 
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pediatric dialysis patients were obtained from each center through 
a questionnaire completed by pediatric nephrologists. Center pro-
tocols for monitoring protective antibody titers after vaccination 
were also noted. Local Ethical Committee approval was obtained.
Results
Of the above mentioned centers, 7 of the pediatric ne-
phrology centers were in children’s hospitals and 11 were 
located in general hospitals. Also, 14 centers had PD and 
HD nurses, 3 centers had only PD nurses, and 1 had only 
HD nurse.
The vaccinations of dialysis patients were recorded by 
pediatric nephrologists in 13 centers, by both pediatric 
nephrologist and dialysis nurse in 3 centers, and by health 
care center in the remaining 2 centers. The national uni-
versal vaccination recommendations and national rec-
ommendations for children with chronic disease or risk 
according to the European Center for Disease Prevention 
and Control and World Health Organization are summa-
rized in Table 1. 
All vaccines included in the universal vaccination pro-
grams were also recommended for children with CKD, 
except those who are already on immunosuppression or 
have an underlying immune deficiency. However, in sev-
eral countries, some vaccines not included in the nation-
al universal program were recommended for children 
with chronic diseases, namely in this case for children 
with CKD/dialysis including vaccines against Bacille 
Calmette Guerin (BCG), Hepatitis A and B, influenza, 
varicella, and meningococcus. All countries recom-
mended pneumococcal conjugated vaccine for CKD pa-
tients, if not vaccinated before. Following completion of 
pneumococcal conjugated vaccine series, dialysis pa-
tients were routinely given the pneumococcal polysac-
charide vaccine in 9 out of 18 centers (7 countries). Pneu-
mococcal vaccines were paid by social security in all 
countries for children at risk.
Hepatitis B booster was recommended when titers fall 
below protective levels in 17 centers in which protective 
antibody titers were measured. Double dosage of hepati-
tis B vaccine is routinely used in children on dialysis in 
those centers except Polish center. In 16 of 18 centers, 
dialysis patients were vaccinated against influenza virus 
annually, a double dose was used in 3 countries (Table 1, 
2). Center-based reports revealed that purified protein 
derivative (PPD) skin test or Quantiferon test was applied 
in 12 of 18 centers during pre-RTx preparations (Table 
2).
Rejection of vaccination by parents was reported from 
4 centers (Germany, Italy, and Lithuania) related to pa-
rental beliefs about possible adverse reactions of vaccines 
or for ideological reasons including the impression that 
the whole vaccination campaign is driven by pharmaceu-
tical companies and lack of knowledge about underlying 
diseases and potential consequences of vaccine prevent-
able diseases in these cases.
Centers’ policy for screening antibody titers for HBV, 
HAV, MMR, and VZV at regular intervals or after com-
pletion of vaccination or during pre-RTx preparation are 
displayed in Table 3. In 17 out of 18 centers, protective 
antibody titers were measured for HBV and in 13 centers, 
for HAV, either during dialysis period or during pre-RTx 
preparation or both. A total of 11 of 18 centers reported 
HBV antibody measurement both during the dialysis pe-
riod and before RTx. HAV antibody titers were reported 
to be monitored in 8 of 18 centers during dialysis period 
and in 11 of 18 centers before RTx. Only in 6 of 18 centers, 
hepatitis A and B antibody titers were checked during di-
alysis and before transplantation. Also, 12 centers report-
ed checking MMR antibodies during dialysis or pre-RTx 
preparations. VZV antibodies were followed in 10 of 18 
centers during dialysis period and in 12 of 18 centers be-
fore RTx. MMR and VZV antibody measurements were 
applied during both periods in 6 centers and 8 centers, 
respectively. 
Discussion
Recently, widespread vaccination in the pediatric pop-
ulation has significantly reduced the spread of vaccine-
preventable infections, which also reduces the risk of in-
fections in children with CKD. Nevertheless, children 
with CKD are looked upon as a risk population for severe 
infections due to their defective immune status. Children 
with CKD generally produce protective antibodies fol-
lowing primary vaccinations; however, some children on 
dialysis and after RTx may not respond optimally due to 
reduced titer or duration of antibodies after immuniza-
tion and may require repeated vaccination [3, 4, 9]. Fur-
thermore vaccination coverage among these children 
may be suboptimal due to frequent hospitalizations and 
long hospital stays, relatively high cost of vaccines which 
are not provided by the national health system in some 
countries, limited knowledge among families, and health-
care providers about the importance of vaccination and 
concerns about the safety, immunogenicity, and efficacy 
of vaccines [5, 10]. In our survey, all centers had dialysis 




nurses. The record of vaccinations of dialysis patients was 
assigned to pediatric nephrologists in 13 centers, to both 
pediatric nephrologist and dialysis nurses in 3 centers. 
Since dialysis nurses have a closer contact with patients 
compared to doctors, they may more successfully collect 
update vaccination records.
In this study, based on a European survey including 18 
centers from 12 countries, we observed that most of the 
currently recommended vaccines are provided free of 
cost by the national health system to CKD and dialysis 
patients with only a few exceptions and some differences 
among countries (Table 1). Vaccination policies across 
Europe are routinely reviewed and coming close to an 
ideal immunization schedule. However, in practice, in 
addition to the aforementioned reasons, incomplete vac-
cination records due to heavy work load, the complex na-
Table 1. National universal vaccination recommendations and recommendations for children with chronic disease or risk (ECDC, 
WHO) in 12 European Countries
Recommendation Included in national universal 
immunization programme 
Recommended for children 
with chronic disease/risk 
No recommendation
Vaccine
BCG GR, LT, PL, TR, UK1 CZ, FI, FR, BE, DE, ES, IT2
DTaP/DTwP All countries3 All countries –
Hib All countries All countries –
IPV All countries All countries –
OPV* TR – BE, CZ, DE, ES, FI, FR, GR, IT, 
LT, PL, UK 
Hepatitis A CZ, GR, TR, PL4 BE, ES, IT, FI DE, FR, LT, UK
Hepatitis B** BE, CZ, DE, ES, FR, GR, IT, LT,  
PL, TR
FI, UK –
PCV All countries All countries –
PPSV – CZ, DE, FR, GR BE, ES, FI, IT, LT, PL, TR, UK 
Influenzae virus*** PL5 BE, CZ, DE, ES, FI, FR, GR,  
IT, LT, TR, UK
–
Rotavirus BE, CZ6, FI, DE, GR, PL4, UK – ES, FR, IT, LT, TR 
MMR All countries All countries –
Varicella zoster CZ6, DE, GR, ES, IT, TR BE, FR, PL, UK, FI LT 
HPV BE7, CZ4, DE7, ES7, FI, FR7, GR7, 
IT7, LT, PL4, UK7
– TR 
Meningococcal vaccines BE, CZ4, DE, ES, FR, GR, IT, PL5, 
UK 
FI LT, TR
Belgium (BE),  Czech Republic (CZ), Finland (FI), France (FR), Germany (DE), Greece (GR), Italy (IT), Lithuania (LT), Poland (PL), 
Spain (ES), Turkey (TR) and United Kingdom (UK).
BCG, Bacille Calmette-Guérin vaccine; DTaP, diphtheria and tetanus toxoid with acellular pertussis vaccine; DTwP, diphtheria and 
tetanus toxoid with whole cell pertussis vaccine; IPV, inactive polio vaccine; HAV, hepatitis A virus; HBV, hepatitis B virus; Hib, haemo-
philus influenzae type b; HPV, human papillomavirus; MMR, Measles Mumps Rubella; OPV, oral polio vaccine; PCV, pneumococcal 
conjugated vaccine; PPSV, pneumococcal polysaccharide vaccine.
1 Recommended to all CKD children below 6 years of age and to children above 6 years if quantiferon negative. 2 Recommended for 
health workers at high risk. 3 DTwP only in Poland (in Poland DTwP is in national programme; DTaP is recommended for risk groups). 
4 Recommended but not funded by the National Health system. 5 Recommended, but not mandatory and not funded by the National 
Health system. 6 Recommended only. Not included in the national immunization schedule. 7 Recommended for girls. * Not recommen-
ded in immunocompromised children, ** Double dose in CKD/dialysis patients except Poland, *** Double dose in CKD/dialysis patients 
in Finland, Spain and UK.
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ture of the disease course in CKD requiring detailed clin-
ical and laboratory examinations during clinical visits, 
comorbid conditions, frequent non-communicable in-
fectious diseases, early neonatal onset of CKD, and nega-
tive basic attitude of parents in some countries may hin-
der or delay scheduled routine immunization. Parental 
refusal of vaccines is a growing concern for the increased 
incidence of vaccine-preventable diseases [11]. Reasons 
why parents delay, refuse, or hesitate to vaccinate their 
children are religious beliefs, philosophical reasons such 
as believing that natural immunity is better than that ac-
quired through vaccination, safety concerns, and desire 
for more information from healthcare professionals [11].
According to our data, refusal of vaccination was report-
ed from 4 centers because of parental beliefs about pos-
sible adverse reactions due to the vaccines or for ideo-
logical reasons. These families should be informed about 
how essential vaccination is before RTx and if a family 
refuses to vaccinate their child they might even prevent 
their own child’s chance of receiving an allograft simply 
because of their prejudice.
In this survey, immunization against diphtheria, tet-
anus, pertussis, H. influenzae type b, polio, MMR, and 
pneumococcus (conjugated vaccine) are included in the 
universal immunization schedule in all countries, while 
vaccination against HAV and HBV, VZV, tuberculosis, 
rotavirus, human papilloma virus, and meningococcus 
are not. Hepatitis B has become very rare in some West-
Table 2. Center policy for particular tests and vaccines in CKD and dialysis patients
Applied (n) Not applied (n)
PPD skin test or Quantiferon before RTx DE, ES, FR, GR (I), IT (I, III), PL, TR (I–IV), 
UK (12)
BE, CZ, FI, GR II, IT II, LT (6)
Annual inactive influenza virus vaccine BE, CZ, DE, ES, FI, GR (I, II), IT (I–III), PL,  
TR (I–IV), UK (16)
FR, LT (2)
PPSV after completion of PCV CZ, DE, ES, FR, GR (I, II), TR (I, III), UK (9) BE, FI, IT (I–III), LT, PL, TR (II, IV) 
(9)
Belgium (BE),  Czech Republic (CZ), Finland (FI), France (FR), Germany (DE), Greece (GR), Italy (IT), Lithuania (LT), Poland (PL), 
Spain (ES), Turkey (TR) and United Kingdom (UK). CKD, chronic kidney disease; PCV, pneumococcal conjugated vaccine; PPSV, 
pneumococcal polysaccharide vaccine; PPD, purified protein derivative skin test.
Table 3. Centers’ policy for antibody screening
Policy Antibody (IgG) titer measurement after completion of 
vaccination or at regular intervals (n/%)
Antibody (IgG) titer measurement before RTx, despite 
proper vaccination or disease history (n/%)
yes no yes no
HBV BE, CZ, DE, ES, FR, GR (I, II), 
IT III, PL, TR (I–IV), UK 
(14/77.7)
FI, IT (I, II), LT (4/22.2) BE, CZ, FR, GR (I, II), 
IT (I–III), LT, PL, TR (I–IV) 
(14/77.7)
DE, ES, FI, UK (4/22.2)
HAV BE, CZ, DE, ES, FR, TR (I, III, 
IV) (8/44.4)
FI, GR (I, II), IT (I–III), 
LT, PL, TR II, UK (9/50)
BE, CZ, FR, GRI, IT (I–III), 
TR (I–IV) (11/61.1)
DE, ES, FI, GR II, LT, 
PL, UK (7/38.8)
MMR BE, CZ, DE, ES, FR, GRI, TR (I, 
III), UK (9/50)
FI, GR II, IT (I–III), LT, 
PL, TR (II, IV) (9/50)
BE, CZ, FR, GRI, IT (I, II), 
TR (I–III) (9/50)
DE, ES, FI, GR II, IT III, 
LT, PL, TR IV, UK 
(9/50)
VZV BE, CZ, DE, ES, FR, GRI,  
IT III, TR (I, III), UK (10/50)
FI, GR II, IT (I, II), LT, PL, 
TR (II, IV) (8/44.4)
BE, CZ, FR, GR I, IT (I–III), 
LT, TR (I–IV) (12/66.6)
DE, ES, FI, GR II, PL, 
UK (6/33.3)
Belgium (BE), Czechia (CZ), Finland (FI), France (FR), Germany (DE), Greece (GR), Italy (IT), Lithuania (LT), Poland (PL), Spain 
(ES), Turkey (TR) and United Kingdom (UK). HAV, hepatitis A virus; HBV, hepatitis B virus; MMR, Measles Mumps Rubella; 




ern countries due to vaccination programs. However, it 
is still highly prevalent in other areas, affecting up to 
one-third of dialyzed children [4]. Hepatitis B vaccina-
tion is applied to dialysis patients in all surveyed cen-
ters, and is administered as augmented (double) shots 
in 11 countries. Hepatitis B antibodies are regularly 
checked in the vast majority (17) of the centers and 
augmented boosters are given when titers decline below 
protective levels. Although HAV vaccine is routinely 
administered only in Turkey, Poland, Czech Republic, 
and Greece as well as in 4 additional countries (Bel-
gium, Finland, Spain, and Italy), it is indicated for risk 
groups.
BCG vaccine is routinely performed in 5 countries 
(Greece, Lithuania, Poland, Turkey, and the UK), while 
PPD or Quantiferon test is applied to CKD patients in 12 
centers from 8 countries. The difference among national 
immunization programs may be partly due to the low 
prevalence of tuberculosis and hepatitis A in some 
 European countries, so that health authorities do not rec-
ommend vaccines against them.
Influenza virus immunization is included in the na-
tional program for universal vaccination only in Finland. 
However, high risk influenza virus vaccination is includ-
ed in all the countries studied and is paid by social secu-
rity in all countries except Poland. Despite this, 2 centers 
from 2 countries in the study reported that they did not 
administer annual influenza vaccination to dialysis pa-
tients. On the other hand, pneumococcal polysaccharide 
vaccine has been officially included in the national pro-
gram to be applied to children with chronic disease in not 
only 4 countries, but also 9 centers from 7 countries re-
ported to administer polysaccharide vaccine to their CKD 
patients. In the US, a recent study showed that influenza 
and pneumococcal vaccination rates among children 
with CKD remained low despite the inclusion of these 
vaccines as quality and performance indicators for ESRD 
facilities by Medicaid: only one third of children on di-
alysis or with an RTx who were 14 years or younger re-
ceived influenza vaccine between 2008 and 2011. Pneu-
mococcal vaccination rates were even lower during the 
same time period; about 20% of adolescents and just 10% 
of children received pneumococcal vaccinations [5, 12]. 
Since prophylactic vaccinations against influenza viruses 
and pneumococci can reduce disease burden and rates of 
hospitalization due to infection, seasonal influenza vac-
cination is recommended for patients with CKD, despite 
inferior efficacy among these patients [13, 14]. 
VZV vaccine is recommended for all children in 6 
countries (Czech Republic, Germany, Greece, Spain, 
 Italy, and Turkey), and only for risk groups in 5 countries 
(Belgium, France, Finland, Poland, and the United 
 Kingdom). Again, in practice, booster or a second dose of 
some vaccines (measles, pneumococcus, varicella, influ-
enza, and hepatitis) are not routinely given in certain cen-
ters.
In CKD and dialysis patients, there is no evidence 
that vaccination including live virus vaccines leads to 
reactivation of an underlying immune-related renal dis-
ease or aggravates CKD [4]. Inactivated or component 
vaccines have not shown to have any deleterious effect 
on renal function after RTx, and in particular, there was 
no evidence of an increased rate of graft rejection [4]. 
Most guidelines do not recommend live virus vaccines 
after RTx. However, 2 studies on live virus vaccination 
(varicella and measles) after RTx did not show any com-
plications attributable to the vaccine except 1 out of 17 
children with mild vaccination varicella [15, 16]. De-
spite these encouraging reports, live vaccines should 
better be administered before RTx. According to our 
survey, patients are currently vaccinated against these 
viruses before RTx. But a decade ago, a fatal measles in-
fection in a pediatric RTx patient was reported from 
Turkey. He was born before 1980 when routine measles 
vaccination had just started in Turkey and transplanted 
abroad without antibody screening before the proce-
dure [6]. Measles vaccine is now included in all national 
programs with 1 or 2 doses. On the contrary, varicella 
vaccine is not included in all national programs. Con-
sidering this, documentation of wild type infection his-
tory, immunization records, or protective antibody 
screening seem to be the best strategy to be adopted in 
pediatric renal centers. This may be an important issue 
not only for newly referred patients, but also for patients 
coming from foreign countries and for immigrant pa-
tients.
The duration of protection offered by standard vac-
cine administration is shorter for children with CKD on 
conservative treatment and those on dialysis than for 
healthy children [5]. Children who received RTx can 
have moderately or even severely impaired immune re-
sponses and can remain unprotected after vaccine ad-
ministration. Antibody levels also decrease faster in chil-
dren after RTx [5]. This has been demonstrated in a study 
of 35 children in whom antibody titers against MMR, var-
icella, hepatitis B, diphtheria, and tetanus were deter-
mined 1 month prior to transplantation. Only 26% of 
patients on dialysis listed for transplantation showed 
protective antibody titers against all tested pathogens. 
Particularly, low protection was found for hepatitis B 
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[17]. On the contrary, in Turkey, antibody titers were 
analyzed among children who had been admitted for 
RTx. These children had received age-appropriate vac-
cinations but only 84% had antibody titers positive for 
hepatitis B, 77% for hepatitis A, and 65–73% for mumps, 
measles, rubella, and varicella [18]. In a German study, 
antibody titers against diphtheria, tetanus, and HBV, but 
not varicella, significantly decreased between 1 and 2 
years after immunization in children who received RTx 
[19]. Thus, regular surveillance of specific protective an-
tibody titers against vaccine-preventable diseases (against 
at least measles, varicella, and HBV) is necessary in di-
alysis children and before and after RTx. In our study, we 
evaluated the policy of centers for screening antibody ti-
ters. HBV antibody titers were checked in 17 of 18 cen-
ters, HAV in 13 of 18, VZV in 15 of 18, and MMR in 12 
of 18 before renal transplantation. Antibody screening in 
dialysis patients also varies somewhat among European 
countries. Dialysis patients are revaccinated for HBV 
with double dose vaccine in most centers in spite of a lack 
of data on the efficacy of this strategy in children [20]. 
Double dose influenza vaccine is administered in  Finland, 
Spain, and the UK but as a single dose in the remaining 
countries.
In conclusion, vaccination in children with CKD and 
those on dialysis is an under-recognized area, with varia-
tions in practice across the EU, and deserves more attention 
in pediatric nephrology clinics. Dialysis children and trans-
plant candidates should receive age-appropriate vaccina-
tions before RTx and should be explicitly evaluated about 
vaccination status and protective antibody levels also after 
RTx and administered vaccine booster doses when titers 
decline. Vaccination records must be a routine part of writ-
ten and electronic patient records for CKD patients. Also, 
we recommend completing the immunization before the 
transfer to an adult nephrology clinic. Vaccination policies 
in children with CKD should be routinely reviewed and an 
ideal immunization schedule should be generated.
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